Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tsTACE thermosensitive oxaliplatin gel vs cTACE vs XELOX alone in intrahepatic cholangiocarcinoma
ChiCTR2500105380Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of oxaliplatin and capecitabine in intrahepatic cholangiocarcinoma (ICC) (3 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Overall survival (OS), Objective response rate (ORR) and 1 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
oxaliplatincapecitabine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2500105380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105380.